Mizuho Reiterates Outperform on BridgeBio Pharma, Maintains $106 Price Target

Benzinga Newsdesk www.benzinga.com Negative 74.1%

Neg 74.1% Neu 0% Pos 0%

Mizuho analyst Salim Syed reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and maintains $106 price target.

Comments

No comments yet. Be the first!